Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial | WAPE

Newsbenzinga

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

Jul 7, 2026, 14:21 ET · Published

Article summary

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.

An excerpt from the original article.

Related companies

RPRXRPRXView stock

Comments —

Comment

Loading comments…